Browsing by author "Huddart, Robert"
Now showing items 41-60 of 118
-
Feasibility of magnetic resonance guided radiotherapy for the treatment of bladder cancer.
Hunt, A; Hanson, I; Dunlop, A; Barnes, H; Bower, L; et al. (ELSEVIER IRELAND LTD, 2020-11-01)Whole bladder magnetic resonance image-guided radiotherapy using the 1.5 Telsa MR-linac is feasible. Full online adaptive planning workflow based on the anatomy seen at each fraction was performed. This was delivered within ... -
Feasibility of tumour-focused adaptive radiotherapy for bladder cancer on the MR-linac.
Mitchell, A; Ingle, M; Smith, G; Chick, J; Diamantopoulos, S; et al. (ELSEVIER IRELAND LTD, 2022-07-01)Bladder tumour-focused magnetic resonance image-guided adaptive radiotherapy using a 1.5 Tesla MR-linac is feasible. A full online workflow adapting to anatomy at each fraction is achievable in approximately 30 min. ... -
Features and Management of Late Relapse of Nonseminomatous Germ Cell Tumour.
Jay, APM; Aldiwani, M; O'Callaghan, ME; Pearce, AK; Huddart, RA; et al. (ELSEVIER, 2021-06-07)BACKGROUND: Late relapse (LR) of nonseminomatous germ cell tumour (NSGCT) is uncommon, with limited data published. LR is defined as relapse occurring after a disease-free interval of 2 yr. OBJECTIVE: To review features ... -
From Clinical Trials to Real-life Clinical Practice: The Role of Immunotherapy with PD-1/PD-L1 Inhibitors in Advanced Urothelial Carcinoma.
Hussain, SA; Birtle, A; Crabb, S; Huddart, R; Small, D; et al. (ELSEVIER, 2018-12-01)CONTEXT: A number of PD-1/PD-L1 inhibitors have recently been approved for use in patients with locally advanced or metastatic urothelial carcinoma (UC) on the basis of results from several clinical trials. OBJECTIVE: To ... -
Genomic landscape of platinum resistant and sensitive testicular cancers.
Loveday, C; Litchfield, K; Proszek, PZ; Cornish, AJ; Santo, F; et al. (NATURE PUBLISHING GROUP, 2020-05-04)While most testicular germ cell tumours (TGCTs) exhibit exquisite sensitivity to platinum chemotherapy, ~10% are platinum resistant. To gain insight into the underlying mechanisms, we undertake whole exome sequencing and ... -
Histological Features of Sporadic and Familial Testicular Germ Cell Tumors Compared and Analysis of Age-Related Changes of Histology.
Stang, A; McMaster, ML; Sesterhenn, IA; Rapley, E; Huddart, R; et al. (MDPI, 2021-04-01)This study aimed to compare histological features of familial and sporadic testicular germ cell tumors (TGCTs) and surrounding parenchyma, since discriminating features might be etiologically relevant and clinically useful. ... -
Hypofractionated radiotherapy in locally advanced bladder cancer: an individual patient data meta-analysis of the BC2001 and BCON trials.
Choudhury, A; Porta, N; Hall, E; Song, YP; Owen, R; et al. (ELSEVIER SCIENCE INC, 2021-02-01)BACKGROUND: Two radiotherapy fractionation schedules are used to treat locally advanced bladder cancer: 64 Gy in 32 fractions over 6·5 weeks and a hypofractionated schedule of 55 Gy in 20 fractions over 4 weeks. Long-term ... -
Identification of 19 new risk loci and potential regulatory mechanisms influencing susceptibility to testicular germ cell tumor.
Litchfield, K; Levy, M; Orlando, G; Loveday, C; Law, PJ; et al. (NATURE PUBLISHING GROUP, 2017-07-01)Genome-wide association studies (GWAS) have transformed understanding of susceptibility to testicular germ cell tumors (TGCTs), but much of the heritability remains unexplained. Here we report a new GWAS, a meta-analysis ... -
Identification of nine new susceptibility loci for testicular cancer, including variants near DAZL and PRDM14.
Ruark, E; Seal, S; McDonald, H; Zhang, F; Elliot, A; et al. (NATURE PUBLISHING GROUP, 2013-06-01)Testicular germ cell tumor (TGCT) is the most common cancer in young men and is notable for its high familial risks. So far, six loci associated with TGCT have been reported. From genome-wide association study (GWAS) ... -
IGF1R signalling in testicular germ cell tumour cells impacts on cell survival and acquired cisplatin resistance.
Selfe, J; Goddard, NC; McIntyre, A; Taylor, KR; Renshaw, J; et al. (WILEY, 2018-02-01)Testicular germ cell tumours (TGCTs) are the most frequent malignancy and cause of death from solid tumours in the 20- to 40-year age group. Although most cases show sensitivity to cis-platinum-based chemotherapy, this is ... -
Imaging Modality and Frequency in Surveillance of Stage I Seminoma Testicular Cancer: Results From a Randomized, Phase III, Noninferiority Trial (TRISST).
Joffe, JK; Cafferty, FH; Murphy, L; Rustin, GJS; Sohaib, SA; et al. (LIPPINCOTT WILLIAMS & WILKINS, 2022-08-01)PURPOSE: Survival in stage I seminoma is almost 100%. Computed tomography (CT) surveillance is an international standard of care, avoiding adjuvant therapy. In this young population, minimizing irradiation is vital. The ... -
Imaging of testicular germ cell tumours.
Dalal, PU; Sohaib, SA; Huddart, R (E-MED LTD, 2006-09-07)In testicular germ cell tumour (GCT), imaging plays a central role in assessment of tumour bulk, sites of metastases, monitoring response to therapy, surgical planning and accurate assessment of disease at relapse. The ... -
International survey; current practice in On-line adaptive radiotherapy (ART) delivered using Magnetic Resonance Image (MRI) guidance.
McNair, HA; Wiseman, T; Joyce, E; Peet, B; Huddart, RA (Elsevier BV, 2020-12-01)BACKGROUND AND PURPOSE: The uptake of new technologies has varied internationally and there have often been barriers to implementation. On-line adaptive radiotherapy (ART) promises to improve patient outcome. This survey ... -
Large-scale Analysis Demonstrates Familial Testicular Cancer to have Polygenic Aetiology.
Loveday, C; Law, P; Litchfield, K; Levy, M; Holroyd, A; et al. (ELSEVIER SCIENCE BV, 2018-09-01)UNLABELLED: Testicular germ cell tumour (TGCT) is the most common cancer in young men. Multiplex TGCT families have been well reported and analyses of population cancer registries have demonstrated a four- to eightfold ... -
Large-scale Sequencing of Testicular Germ Cell Tumour (TGCT) Cases Excludes Major TGCT Predisposition Gene.
Litchfield, K; Loveday, C; Levy, M; Dudakia, D; Rapley, E; et al. (2018-06)Testicular germ cell tumour (TGCT), the most common cancer in young men, has a significant heritable basis that has long raised questions as to the existence of underlying major high-penetrance susceptibility gene(s). To ... -
Long-term outcomes with intensive induction chemotherapy (carboplatin, bleomycin, vincristine and cisplatin/bleomycin, etoposide and cisplatin) and standard bleomycin, etoposide and cisplatin in poor prognosis germ cell tumours: A randomised phase II trial (ISRCTN53643604).
Cafferty, FH; White, JD; Shamash, J; Hennig, I; Stenning, SP; et al. (ELSEVIER SCI LTD, 2020-03-01)BACKGROUND: Up to 50% of men with poor prognosis, non-seminoma germ cell tumours (GCTs) die with standard BEP (bleomycin, etoposide and cisplatin) chemotherapy. An intensive regimen, CBOP/BEP (carboplatin, bleomycin, ... -
Magnetic resonance imaging sequence evaluation of an MR Linac system; early clinical experience.
Eccles, CL; Adair Smith, G; Bower, L; Hafeez, S; Herbert, T; et al. (Elsevier BV, 2019-12-16)OBJECTIVES: To systematically identify the preferred magnetic resonance imaging (MRI) sequences following volunteer imaging on a 1.5 Tesla (T) MR-Linear Accelerator (MR Linac) for future protocol development. METHODS: ... -
Magnetic Resonance-guided Radiotherapy - Can We Justify More Expensive Technology?
Tree, AC; Huddart, R; Choudhury, A (ELSEVIER SCIENCE LONDON, 2018-11-01) -
Magnitude of observer error using cone beam CT for prostate interfraction motion estimation: effect of reducing scan length or increasing exposure.
McNair, HA; Harris, EJ; Hansen, VN; Thomas, K; South, C; et al. (BRITISH INST RADIOLOGY, 2015-10-01)OBJECTIVE: Cone beam CT (CBCT) enables soft-tissue registration to planning CT for position verification in radiotherapy. The aim of this study was to determine the interobserver error (IOE) in prostate position verification ... -
Management of Fibroblast Growth Factor Inhibitor Treatment-emergent Adverse Events of Interest in Patients with Locally Advanced or Metastatic Urothelial Carcinoma.
Siefker-Radtke, AO; Necchi, A; Park, SH; García-Donas, J; Huddart, RA; et al. (ELSEVIER, 2023-04-01)BACKGROUND: Erdafitinib is indicated for the treatment of adults with locally advanced/metastatic urothelial carcinoma and susceptible FGFR3/2 alterations progressing on/after one or more lines of prior platinum-based ...